By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CRISPR Therapeutics 

675 West Kendall Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-580-9212 Fax: n/a


CRISPR Therapeutics is a leading gene editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing platform. CRISPR is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working on a number of wholly-owned programs to treat serious diseases with high unmet need.


November 2013


Founders: Rodger Novak, Emmanuelle Charpentier, Shaun Foy

Scientific Founders: Chad Cowan, Daniel Anderson, Stephen Elledge, Craig Mello, Matthew Porteus

CEO and Co-founder: Rodger Novak

CFO: Marc Becker

CSO (Scientific): Sven Ante (Bill) Lundberg


Please click here for CRISPR Therapeutics job opportunities.


Key Statistics

Ownership: Public

Web Site: CRISPR
Symbol: CRSP

Company News
CRISPR (CRSP) Announces The Presentation Of Data On Its Lead Program At The Upcoming 22nd European Hematology Association Annual Congress 5/18/2017 10:19:53 AM
CRISPR (CRSP) And Collaborators At The University of Florida Awarded Target ALS Grant To Develop CRISPR/Cas9-Based Approaches For ALS 5/16/2017 10:42:11 AM
CRISPR (CRSP) Reports Financial Results For The Three Months Ended March 31, 2017 And Provides Business Update 5/11/2017 8:54:22 AM
CRISPR (CRSP) Announces Exclusive License Of Lipid Nanoparticle Technologies Developed At MIT 5/8/2017 10:28:56 AM
CRISPR (CRSP) Appoints Samarth Kulkarni, Ph.D. As President, Expanding Role Beyond Chief Business Officer To Oversee U.S. Operations 5/4/2017 10:49:44 AM
Intellia And CRISPR (CRSP) Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes 4/26/2017 10:32:20 AM
CRISPR (CRSP) And Casebia Therapeutics Announce Exclusive Development And Option Agreement With StrideBio 4/17/2017 8:18:28 AM
Patent Fight Continues as CRISPR (CRSP), Intellia, Caribou Biosciences and ERS Genomics Appeal CRISPR Decision 4/13/2017 8:19:07 AM
CRISPR (CRSP) And Casebia Therapeutics Announce Commercial License Agreement With MaxCyte, Inc. 3/14/2017 8:09:05 AM
CRISPR (CRSP) Announces The Appointment Of Jon Terrett, Ph.D. To Head Of Immuno-Oncology Research And Translation 2/28/2017 10:19:02 AM